CALGARY, Alberta, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the significant clinical advances of ZEN-3694, the Company’s lead compound being ...
Zenith Epigenetics offers a differentiated approach to bromodomain extra terminal (BET) inhibition. The company's lead candidate, ZEN-3694, has demonstrated a synergistic ability to resensitize the ...
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the first ...
Article ‘Count’ and ‘Share’ for Zenith Epigenetics Corp. based on listed parameters only. The articles listed below published by authors from Zenith Epigenetics Corp., organized by journal and article ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results